ImmuPharma PLC (IMM) — Working Capital to Net Assets Ratio
ImmuPharma PLC (IMM) has a Working Capital to Net Assets ratio of 76.5% as of June 2025. Working capital of GBX257.41K (current assets of GBX1.50 Million minus current liabilities of GBX1.24 Million) is measured against net assets of GBX336.70K. A higher ratio indicates strong short-term liquidity financed by the equity base. See debt-free asset ratio of ImmuPharma PLC to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
ImmuPharma PLC Working Capital to Net Assets (2004–2024)
This chart shows how ImmuPharma PLC's Working Capital to Net Assets ratio has evolved across 22 annual periods from 2004 to 2024. As of June 2025, the ratio stands at 76.5%, reflecting working capital of GBX257.41K against net assets of GBX336.70K GBX. Check IMM goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for ImmuPharma PLC (2004–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for ImmuPharma PLC from 2004 to 2024, covering 22 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see market cap of ImmuPharma PLC.
| Year | WC/NA Ratio | Working Capital (GBX) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 117.0% | GBX-635.00K | GBX-542.86K | GBX884.87K | GBX1.52 Million | ▲ +147.5 pp |
| 2023 | -30.5% | GBX-321.92K | GBX1.06 Million | GBX1.34 Million | GBX1.67 Million | ▼ -65.7 pp |
| 2022 | 35.2% | GBX887.63K | GBX2.52 Million | GBX2.34 Million | GBX1.45 Million | ▼ -4.7 pp |
| 2021 | 39.9% | GBX1.76 Million | GBX4.41 Million | GBX3.35 Million | GBX1.58 Million | ▼ -24.0 pp |
| 2020 | 63.9% | GBX6.17 Million | GBX9.65 Million | GBX7.43 Million | GBX1.26 Million | ▲ +6.0 pp |
| 2019 | 57.9% | GBX3.05 Million | GBX5.27 Million | GBX3.58 Million | GBX531.87K | ▼ -7.7 pp |
| 2018 | 65.6% | GBX5.00 Million | GBX7.62 Million | GBX6.01 Million | GBX1.01 Million | ▼ -25.2 pp |
| 2017 | 90.8% | GBX3.24 Million | GBX3.57 Million | GBX4.37 Million | GBX1.13 Million | ▲ +0.2 pp |
| 2016 | 90.6% | GBX5.02 Million | GBX5.55 Million | GBX5.97 Million | GBX944.35K | ▲ +21.4 pp |
| 2015 | 69.1% | GBX1.17 Million | GBX1.69 Million | GBX2.41 Million | GBX1.24 Million | ▼ -21.2 pp |
| 2014 | 90.3% | GBX5.15 Million | GBX5.71 Million | GBX6.15 Million | GBX990.97K | ▼ -11.0 pp |
| 2013 | 101.3% | GBX5.47 Million | GBX5.40 Million | GBX6.51 Million | GBX1.03 Million | ▼ -2.2 pp |
| 2012 | 103.5% | GBX8.71 Million | GBX8.42 Million | GBX9.77 Million | GBX1.05 Million | ▲ +3.2 pp |
| 2011 | 100.3% | GBX12.54 Million | GBX12.51 Million | GBX13.49 Million | GBX946.00K | ▲ +0.4 pp |
| 2010 | 99.9% | GBX15.96 Million | GBX15.97 Million | GBX16.77 Million | GBX811.00K | ▲ +1.8 pp |
| 2009 | 98.2% | GBX17.75 Million | GBX18.08 Million | GBX23.89 Million | GBX6.13 Million | ▼ -1.4 pp |
| 2008 | 99.6% | GBX11.19 Million | GBX11.24 Million | GBX12.58 Million | GBX1.39 Million | ▲ +13.4 pp |
| 2007 | 86.2% | GBX2.63 Million | GBX3.05 Million | GBX3.33 Million | GBX704.00K | ▼ -7.8 pp |
| 2006 | 93.9% | GBX5.53 Million | GBX5.89 Million | GBX6.56 Million | GBX1.03 Million | ▲ +25.0 pp |
| 2006 | 69.0% | GBX1.73 Million | GBX2.50 Million | GBX2.85 Million | GBX1.12 Million | ▼ -31.0 pp |
| 2005 | 100.0% | GBX993.00K | GBX993.00K | GBX1.01 Million | GBX14.00K | ▲ +0.0 pp |
| 2004 | 100.0% | GBX978.00K | GBX978.00K | GBX980.00K | GBX2.00K | — |